These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

662 related items for PubMed ID: 23082000

  • 1. Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models.
    Zhang J, Zhang L, Su X, Li M, Xie L, Malchers F, Fan S, Yin X, Xu Y, Liu K, Dong Z, Zhu G, Qian Z, Tang L, Schöttle J, Zhan P, Ji Q, Kilgour E, Smith PD, Brooks AN, Thomas RK, Gavine PR.
    Clin Cancer Res; 2012 Dec 15; 18(24):6658-67. PubMed ID: 23082000
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma.
    Koole K, Brunen D, van Kempen PM, Noorlag R, de Bree R, Lieftink C, van Es RJ, Bernards R, Willems SM.
    Clin Cancer Res; 2016 Aug 01; 22(15):3884-93. PubMed ID: 26936917
    [Abstract] [Full Text] [Related]

  • 4. Characterization of FGFR1 Locus in sqNSCLC Reveals a Broad and Heterogeneous Amplicon.
    Rooney C, Geh C, Williams V, Heuckmann JM, Menon R, Schneider P, Al-Kadhimi K, Dymond M, Smith NR, Baker D, French T, Smith PD, Harrington EA, Barrett JC, Kilgour E.
    PLoS One; 2016 Aug 01; 11(2):e0149628. PubMed ID: 26905262
    [Abstract] [Full Text] [Related]

  • 5. A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers.
    Paik PK, Shen R, Berger MF, Ferry D, Soria JC, Mathewson A, Rooney C, Smith NR, Cullberg M, Kilgour E, Landers D, Frewer P, Brooks N, André F.
    Clin Cancer Res; 2017 Sep 15; 23(18):5366-5373. PubMed ID: 28615371
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression.
    Kotani H, Ebi H, Kitai H, Nanjo S, Kita K, Huynh TG, Ooi A, Faber AC, Mino-Kenudson M, Yano S.
    Oncogene; 2016 Jul 07; 35(27):3587-97. PubMed ID: 26549034
    [Abstract] [Full Text] [Related]

  • 8. FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547.
    Xie L, Su X, Zhang L, Yin X, Tang L, Zhang X, Xu Y, Gao Z, Liu K, Zhou M, Gao B, Shen D, Zhang L, Ji J, Gavine PR, Zhang J, Kilgour E, Zhang X, Ji Q.
    Clin Cancer Res; 2013 May 01; 19(9):2572-83. PubMed ID: 23493349
    [Abstract] [Full Text] [Related]

  • 9. FGFR Inhibition Enhances Sensitivity to Radiation in Non-Small Cell Lung Cancer.
    SenthilKumar G, Fisher MM, Skiba JH, Miller MC, Brennan SR, Kaushik S, Bradley ST, Longhurst CA, Buehler D, Nickel KP, Iyer G, Kimple RJ, Baschnagel AM.
    Mol Cancer Ther; 2020 Jun 01; 19(6):1255-1265. PubMed ID: 32371583
    [Abstract] [Full Text] [Related]

  • 10. The FGFR1 V561M Gatekeeper Mutation Drives AZD4547 Resistance through STAT3 Activation and EMT.
    Ryan MR, Sohl CD, Luo B, Anderson KS.
    Mol Cancer Res; 2019 Feb 01; 17(2):532-543. PubMed ID: 30257990
    [Abstract] [Full Text] [Related]

  • 11. A miRNA Panel Predicts Sensitivity of FGFR Inhibitor in Lung Cancer Cell Lines.
    Ren S, Rivard CJ, Yu H, Genova C, Rozenboom L, Gao D, Hinz TK, Rikke BA, Wynes MW, Caldwell C, Agustoni F, Kenichi Suda, Jiang T, Zhou C, Heasley LE, Hirsch FR.
    Clin Lung Cancer; 2018 Sep 01; 19(5):450-456. PubMed ID: 30146263
    [Abstract] [Full Text] [Related]

  • 12. Kinome RNAi Screens Reveal Synergistic Targeting of MTOR and FGFR1 Pathways for Treatment of Lung Cancer and HNSCC.
    Singleton KR, Hinz TK, Kleczko EK, Marek LA, Kwak J, Harp T, Kim J, Tan AC, Heasley LE.
    Cancer Res; 2015 Oct 15; 75(20):4398-406. PubMed ID: 26359452
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Exogenous Restoration of TUSC2 Expression Induces Responsiveness to Erlotinib in Wildtype Epidermal Growth Factor Receptor (EGFR) Lung Cancer Cells through Context Specific Pathways Resulting in Enhanced Therapeutic Efficacy.
    Dai B, Yan S, Lara-Guerra H, Kawashima H, Sakai R, Jayachandran G, Majidi M, Mehran R, Wang J, Bekele BN, Baladandayuthapani V, Yoo SY, Wang Y, Ying J, Meng F, Ji L, Roth JA.
    PLoS One; 2015 Oct 15; 10(6):e0123967. PubMed ID: 26053020
    [Abstract] [Full Text] [Related]

  • 18. FGFR1 overexpression in non-small cell lung cancer is mediated by genetic and epigenetic mechanisms and is a determinant of FGFR1 inhibitor response.
    Bogatyrova O, Mattsson JSM, Ross EM, Sanderson MP, Backman M, Botling J, Brunnström H, Kurppa P, La Fleur L, Strell C, Wilm C, Zimmermann A, Esdar C, Micke P.
    Eur J Cancer; 2021 Jul 15; 151():136-149. PubMed ID: 33984662
    [Abstract] [Full Text] [Related]

  • 19. Fibroblast Growth Factor Receptors as Targets for Radiosensitization in Head and Neck Squamous Cell Carcinomas.
    Fisher MM, SenthilKumar G, Hu R, Goldstein S, Ong IM, Miller MC, Brennan SR, Kaushik S, Abel L, Nickel KP, Iyer G, Harari PM, Kimple RJ, Baschnagel AM.
    Int J Radiat Oncol Biol Phys; 2020 Jul 15; 107(4):793-803. PubMed ID: 32298810
    [Abstract] [Full Text] [Related]

  • 20. FGFR1 promotes the stem cell-like phenotype of FGFR1-amplified non-small cell lung cancer cells through the Hedgehog pathway.
    Ji W, Yu Y, Li Z, Wang G, Li F, Xia W, Lu S.
    Oncotarget; 2016 Mar 22; 7(12):15118-34. PubMed ID: 26936993
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.